The following government grants in the FederalGrants.com database contain the term National Institutes of Health in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) |
93.307 |
RFA-MD-19-001 |
| Administrative Supplement for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional) |
93.113, 93.121, 93.242, 93.273, 93.279, 93.286, 93.313, 93.351, 93.361, 93.393, 93.394, 93.395, 93.396, 93.399, 93.846, 93.847, 93.853, 93.855, 93.865, 93.866, 93.867, 93.879 |
PA-19-165 |
| Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed) |
93.847 |
RFA-DK-18-023 |
| Womens HIV Epidemiology Cohort Studies (R01 Clinical Trial Not Allowed) |
93.121, 93.865 |
RFA-HD-19-024 |
| Summer Research Education Experience Program (Clinical Trials Not Allowed R25) |
93.113, 93.273, 93.279, 93.853 |
PAR-19-164 |
| Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 - Clinical Trial Optional) |
93.279 |
RFA-DA-19-032 |
| Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required) |
93.353, 93.393, 93.399 |
RFA-CA-19-033 |
| The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed) |
93.395 |
RFA-CA-19-008 |
| Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R43/R44 - Clinical Trial Optional) |
93.279 |
RFA-DA-19-033 |
| Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed) |
93.847 |
RFA-DK-18-008 |
| The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required) |
93.395 |
RFA-CA-19-007 |
| Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional) |
93.279 |
RFA-DA-19-021 |
| Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required) |
93.847 |
RFA-DK-18-509 |
| Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional) |
93.279 |
RFA-DA-19-022 |
| The Human Biomolecular Atlas Program (HuBMAP): Rapid Implementation of Technologies that Will Accelerate Development of a Framework for Mapping the Human Body at High Resolution (UH3 Clinical Trial Not Allowed) |
93.310 |
RFA-RM-19-002 |
| Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed) |
93.242, 93.279, 93.307, 93.313, 93.399, 93.853, 93.865 |
PAR-19-163 |
| Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed) |
93.213, 93.242, 93.279, 93.307, 93.313, 93.399 |
PAR-19-162 |
| Bioengineering Research Partnerships (U01 Clinical Trial Required) |
93.273, 93.286, 93.866 |
PAR-19-157 |
| Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed) |
93.113, 93.273, 93.286, 93.866 |
PAR-19-156 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) |
93.393, 93.394, 93.395, 93.396, 93.399 |
PAR-19-149 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) |
93.393, 93.394, 93.395, 93.396, 93.399 |
PAR-19-150 |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required) |
93.121 |
PAR-19-151 |
| End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional) |
93.361, 93.399 |
PAR-19-153 |
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Required) |
93.273, 93.286, 93.393, 93.394, 93.395, 93.396, 93.399, 93.853, 93.866 |
PAR-19-159 |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) |
93.233, 93.837, 93.838, 93.839, 93.840 |
PAR-19-155 |
| Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed) |
93.242, 93.279, 93.866 |
PAR-19-146 |
| Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed) |
93.242, 93.279, 93.866 |
PAR-19-147 |
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) |
93.113, 93.121, 93.273, 93.286, 93.393, 93.394, 93.395, 93.396, 93.399, 93.846, 93.853, 93.866 |
PAR-19-158 |
| NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed) |
93.121 |
PAR-19-145 |
| NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed) |
93.121 |
PAR-19-160 |
| NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required) |
93.121 |
PAR-19-161 |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed) |
93.121 |
PAR-19-152 |
| Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) |
93.394 |
RFA-CA-19-024 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) |
93.394 |
RFA-CA-19-023 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) |
93.394 |
RFA-CA-19-026 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) |
93.394 |
RFA-CA-19-025 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) |
93.394 |
RFA-CA-19-027 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) |
93.394 |
RFA-CA-19-028 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) |
93.394 |
RFA-CA-19-019 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) |
93.394 |
RFA-CA-19-020 |
Search Results 3721-3760 of 14606
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 [Next] |
